Clinical Study of Eflornithine After Immunotherapy for High-risk Neuroblastoma（CSHEIN）

Korábbi kezelés

• Prior to enrollment, the disease assessment status was either progressive disease (PD) or relapse (via CT or MRI).

Egyéb

• According to the International Neuroblastoma Risk Group Classification, it has been histologically diagnosed as non high risk NB.
• Positive bone marrow smear.
• Hematological parameters and organ function are not qualified, according to the CI CTC 4.0 adverse reaction grading standard of grade 3 or above.
• The guardian does not agree to participate.

• According to the International Neuroblastoma Risk Group Classification, it has been histologically diagnosed as high-risk NB.
• Under the age of 18.
• The disease assessment status is PR (via CT or MRI) and the bone marrow smear is negative.
• If the residual mass is MIBG negative or MIBG positive and lacks FDG-PET affinity, it is considered evidence that the mass does not represent active disease. Subjects with stable residual tumor mass visible on CT/MRI will be included in the study.
• Qualified hematological parameters and organ function; Refer to the CI CTC 4.0 adverse reaction grading standard of grade 2 and below.
• Eflornithine needs to be activated within 120 days after the completion of previous treatment.